TABLE 2.
Odds ratios for ovarian cancer by hormone regimen, recency and duration of use.
| Any Hormone Therapy | Estrogen alone | Estrogen + Progestin only | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Controls (n=5808) |
Cases (n=751) |
Controls (n=5025) |
Cases (n=647) |
Controls (n=5094) |
Cases (n=566) |
|||||
| N (%) | N (%) | OR (95% CI)a | OR (95% CI)b | N (%) | N (%) | OR (95% CI)b | N (%) | N (%) | OR (95% CI)b | |
| Never use | 4463 (76.8) | 497 (66.2) | 1.00 (Referent) | 1.00 (Referent) | 4463 (88.8) | 497 (76.8) | 1.00 (Referent) | 4463 (87.6) | 497 (87.8) | 1.00 (Referent) |
| Ever use | 1345 (23.2) | 254 (33.8) | 1.55 (1.31–1.83) | 1.57 (1.31–1.87) | 562 (11.2) | 150 (23.2) | 2.33 (1.85–2.95) | 633 (12.4) | 69 (12.2) | 0.94 (0.70–1.26) |
| Current | 1039 (17.9) | 215 (28.6) | 1.63 (1.37–1.95) | 1.69 (1.39–2.05) | 347 (6.9) | 127 (19.6) | 3.19 (2.43–4.17) | 564 (11.1) | 56 (9.9) | 0.85 (0.62–1.17) |
| Former | 305 (5.3) | 39 (5.2) | 1.23 (0.86–1.74) | 1.17 (0.82–1.67) | 215 (4.3) | 23 (3.6) | 1.09 (0.69–1.71) | 66 (1.3) | 13 (2.3) | 1.62 (0.87–3.01) |
| Duration of use (years) | ||||||||||
| <1 | 138 (2.4) | 23 (3.1) | 1.52 (0.96–2.39) | 1.50 (0.94–2.38) | 77 (1.5) | 14 (2.2) | 1.82 (1.00–3.32) | 51 (1.0) | 7 (1.2) | 1.19 (0.53–2.68) |
| 1–4 | 558 (9.6) | 126 (16.8) | 1.84 (1.48–2.29) | 1.94 (1.54–2.43) | 198 (3.9) | 82 (12.7) | 3.68 (2.74–4.94) | 303 (6.0) | 30 (5.3) | 0.85 (0.56–1.28) |
| >5 | 648 (11.2) | 105 (14.0) | 1.30 (1.03–1.64) | 1.24 (0.97–1.60) | 287 (5.7) | 54 (8.3) | 1.44 (1.01–2.03) | 276 (5.4) | 32 (5.7) | 0.99 (0.66–1.49) |
| Recency (years) | ||||||||||
| <1 | 1024 (17.6) | 208 (27.7) | 1.60 (1.34–1.92) | 1.65 (1.36–2.01) | 344 (6.8) | 126 (19.5) | 3.17 (2.42–4.16) | 555 (10.9) | 52 (9.2) | 0.80 (0.57–1.11) |
| 1–4 | 87 (1.5) | 18 (2.4) | 1.76 (1.05–2.97) | 1.85 (1.09–3.14) | 31 (0.6) | 5 (0.8) | 1.55 (0.59–4.08) | 45 (0.9) | 10 (1.8) | 1.94 (0.95–3.94) |
| >5 | 230 (4.0) | 28 (3.7) | 1.21 (0.80–1.82) | 1.12 (0.74–1.70) | 185 (3.7) | 19 (2.9) | 1.06 (0.64–1.74) | 30 ( 0.6) | 7 (1.2) | 1.82 (0.78–4.28) |
a
Adjusted for age at diagnosis, study state, and year of interview.
b
Additionally adjusted for body mass index, oral contraceptive use, tubal ligation, parity, family history of ovarian cancer, hysterectomy, and menopausal status.